Bliss Gvs Pharma Ltd vs Indoco Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 438.1 as of 12 Jun 15:30 . The P/E Ratio of Bliss GVS Pharma Ltd changed from 14.9 on March 2021 to 14.7 on March 2025 . This represents a CAGR of -0.27% over 5 yearsThe P/E Ratio of Indoco Remedies Ltd changed from 28.6 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1018 crore on March 2021 to ₹ 1238 crore on March 2025 . This represents a CAGR of 4.00% over 5 yearsThe Market Cap of Indoco Remedies Ltd changed from ₹ 2658 crore on March 2021 to ₹ 2152 crore on March 2025 . This represents a CAGR of -4.14% over 5 years The revenue of Bliss GVS Pharma Ltd for the Mar '26 is ₹ 268.18 crore as compare to the Dec '25 revenue of ₹ 236.71 crore. This represent the growth of 13.29% The revenue of Indoco Remedies Ltd for the Mar '26 is ₹ 479.31 crore as compare to the Dec '25 revenue of ₹ 446.34 crore. This represent the growth of 7.39% The ebitda of Bliss GVS Pharma Ltd for the Mar '26 is ₹ 55.63 crore as compare to the Dec '25 ebitda of ₹ 50.73 crore. This represent the growth of 9.66% The ebitda of Indoco Remedies Ltd for the Mar '26 is ₹ 53.41 crore as compare to the Dec '25 ebitda of ₹ 26.34 crore. This represent the growth of 102.77% The net profit of Bliss GVS Pharma Ltd changed from ₹ 22.11 crore to ₹ 37 crore over 8 quarters. This represents a CAGR of 29.36% The net profit of Indoco Remedies Ltd changed from ₹ 1.82 crore to ₹ -23.68 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Bliss GVS Pharma Ltd changed from 7.64 % on March 2021 to 7.64 % on March 2025 . This represents a CAGR of 0.00% over 5 yearsThe Dividend Payout of Indoco Remedies Ltd changed from 14.96 % on March 2021 to -21.11 % on March 2025 . This represents a CAGR of NaN% over 5 years .

About Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company has its manufacturing facility at Palghar which is WHO GMP approved.
The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards. The company commenced its business in 1985.
In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR).

About Indoco Remedies Ltd

Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbai-based pharmaceutical company focused on formulations, with some presence in contract manufacturing and research.
The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries.
The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal.

FAQs for the comparison of Bliss GVS Pharma Ltd and Indoco Remedies Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Indoco Remedies Ltd?

Market cap of Bliss GVS Pharma Ltd is 4,646 Cr while Market cap of Indoco Remedies Ltd is 2,297 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Indoco Remedies Ltd?

The stock performance of Bliss GVS Pharma Ltd and Indoco Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Indoco Remedies Ltd?

As of June 15, 2026, the Bliss GVS Pharma Ltd stock price is INR ₹438.1. On the other hand, Indoco Remedies Ltd stock price is INR ₹248.95.

How do dividend payouts of Bliss GVS Pharma Ltd and Indoco Remedies Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Indoco Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.